{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:03:58Z","timestamp":1753877038883,"version":"3.41.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypophosphatasia (HPP) is an inborn error of metabolism caused by loss-of-function variants in the ALPL gene, which encodes the tissue nonspecific isozyme of alkaline phosphatase (ALP). There is no typical phenotype in adults. We used a genotyping first approach to determine whether ALPL pathogenic variants were associated with musculoskeletal symptoms, mineral metabolism abnormalities, and an impact on quality of life. We recruited individuals with a pathogenic (or likely pathogenic) variant in ALPL gene (n\u2009=\u200926) and their relatives (n\u2009=\u200944). We performed genetic tests and compared the relatives with positive (n\u2009=\u200920) and negative (n\u2009=\u200924) genetic test. We applied standard questionnaires and physical tests (Brief Pain Inventory [BPI]; Western Ontario and McMaster Universities Arthritis [WOMAC]; Modified Hypophosphatasia Impact Patient Survey; Short Form of 36 Survey [SF-36]; and the Short Physical Performance Battery). In fasting blood samples, we measured creatinine, calcium, phosphate (P), parathyroid hormone (PTH), ALP, bone ALP, 25OHD-, 1,25(OH)2D, CTX, type 1 procollagen N-terminal peptide (PINP), osteocalcin, and tartrate-resistant acid phosphatase5b (TRACP5b). Relatives with positive genetic test had lower ALP (IU\/L) [32.5(12.8) vs 87.8(32.6) p\u00a0&amp;lt;\u2009.001], bone ALP (ng\/mL) [6.3(4.3, 9.8) vs 17.5 (13.12-25.7) p\u00a0&amp;lt;\u2009.001], PTH (pg\/L) [28.6(20.6, 38.1) vs 40.05(25.7, 52.3) p\u00a0=\u2009.03], and higher PLP(nmol\/L) [162.0 (91.75, 337.5) vs 37.5 (18.25, 60.5) p\u00a0&amp;lt;\u2009.001] and P(mmol\/L) [1.36 (0.18) vs 1.05 (0.2) p\u00a0&amp;lt;\u2009.001]. We did not find significant differences in fractures or musculoskeletal features between the groups. Greater pain scores were observed on BPI in relatives with positive genetic tests, and bone and muscle pain were more often reported by this group, but statistical tests were not significant. No differences were found in physical performance or quality of life. In conclusion, we assessed relatives of individuals with pathogenic or likely pathogenic variants in the ALPL gene regardless of the presence of signs and symptoms. Biochemical abnormalities were more common in gene-positive relatives, but the prevalence of musculoskeletal symptoms was comparable in relatives with positive and negative genetic tests.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf034","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:12:09Z","timestamp":1741122729000},"source":"Crossref","is-referenced-by-count":0,"title":["Family mapping of previously identified patients with pathogenic or likely pathogenic <i>ALPL<\/i> variants using predictive genotyping and detailed phenotyping approach: the FAME case-control study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9227-6076","authenticated-orcid":false,"given":"Tatiane","family":"Vilaca","sequence":"first","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Gossiel","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Delaney","sequence":"additional","affiliation":[{"name":"Sheffield Diagnostic Genetics Service, North East and Yorkshire Genomic Laboratory Hub, Sheffield Children\u2019s NHS Foundation Trust , Sheffield S10 2TH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Baker","sequence":"additional","affiliation":[{"name":"Sheffield Diagnostic Genetics Service, North East and Yorkshire Genomic Laboratory Hub, Sheffield Children\u2019s NHS Foundation Trust , Sheffield S10 2TH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Keigwin","sequence":"additional","affiliation":[{"name":"Sheffield Diagnostic Genetics Service, North East and Yorkshire Genomic Laboratory Hub, Sheffield Children\u2019s NHS Foundation Trust , Sheffield S10 2TH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meena","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]},{"name":"Sheffield Children\u2019s NHS Foundation Trust , Sheffield S10 2TH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025041223222250500_ref1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview for 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"issue":"3","key":"2025041223222250500_ref2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/ajmg.a.37991","article-title":"Molecular and clinical analysis of ALPL in a cohort of patients with suspicion of hypophosphatasia","volume":"173","author":"Tenorio","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2025041223222250500_ref3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00223-022-01039-y","article-title":"Diagnostic approach to patients with low serum alkaline phosphatase","volume":"112","author":"Riancho","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2025041223222250500_ref4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.4130","article-title":"Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry","volume":"35","author":"Seefried","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025041223222250500_ref5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-020-05345-9","article-title":"Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment","volume":"31","author":"Bianchi","year":"2020","journal-title":"Osteoporos Int"},{"issue":"7","key":"2025041223222250500_ref6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/jbmr.2178","article-title":"Clinical and radiographic findings in adults with persistent hypophosphatasemia","volume":"29","author":"McKiernan","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025041223222250500_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540692","article-title":"Challenges in hypophosphatasia: suspicion, diagnosis, genetics, management, and follow-up","author":"Montero-Lopez","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2025041223222250500_ref8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00198-020-05612-9","article-title":"Bone mineral density and fracture risk in adult patients with hypophosphatasia","volume":"32","author":"Genest","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025041223222250500_ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"2025041223222250500_ref10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1359\/jbmr.081253","article-title":"Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia","volume":"24","author":"Whyte","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025041223222250500_ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025041223222250500_ref12","doi-asserted-by":"publisher","first-page":"116947","DOI":"10.1016\/j.bone.2023.116947","article-title":"The global ALPL gene variant classification project: dedicated to deciphering variants","volume":"178","author":"Farman","year":"2024","journal-title":"Bone"},{"volume-title":"ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2024 2024","author":"Durkie","key":"2025041223222250500_ref13"},{"key":"2025041223222250500_ref14"},{"key":"2025041223222250500_ref15","doi-asserted-by":"publisher","first-page":"115795","DOI":"10.1016\/j.bone.2020.115795","article-title":"Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic","volume":"144","author":"Desborough","year":"2021","journal-title":"Bone"},{"key":"2025041223222250500_ref16","first-page":"1","volume-title":"The Brief Pain Inventory User Guide","author":"Cleeland","year":"2009"},{"issue":"12","key":"2025041223222250500_ref17","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"volume-title":"SF-36 Physical and Mental Health Summary Scales. A user's Manual","author":"Ware","key":"2025041223222250500_ref18"},{"issue":"10","key":"2025041223222250500_ref19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","article-title":"Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys","volume":"65","author":"Weber","year":"2016","journal-title":"Metabolism"},{"key":"2025041223222250500_ref20","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.bone.2020.115300","article-title":"Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia","volume":"134","author":"Whyte","year":"2020","journal-title":"Bone"},{"issue":"9","key":"2025041223222250500_ref21","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00198-018-4571-0","article-title":"Abnormal bone turnover in individuals with low serum alkaline phosphatase","volume":"29","author":"L\u00f3pez-Delgado","year":"2018","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025041223222250500_ref22","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00198-022-06536-2","article-title":"Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study","volume":"33","author":"Hepp","year":"2022","journal-title":"Osteoporos Int"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf034\/62196863\/ziaf034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/5\/ziaf034\/62196863\/ziaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/5\/ziaf034\/62196863\/ziaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T23:22:33Z","timestamp":1744500153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf034\/8045195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf034","relation":{},"ISSN":["2473-4039"],"issn-type":[{"type":"electronic","value":"2473-4039"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,27]]},"article-number":"ziaf034"}}